课题基金 / 基金详情

Developing an Oncology Workforce for the 21st Century

Developing an Oncology Workforce for the 21st Century
培养 21 世纪的肿瘤学劳动力
批准号:
10683112
负责人:
OLUFUNMILAYO F. OLOPADE
金额:
$81.32万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
未结题
起止时间:
2010-08-12 至 2025-07-31

项目摘要

项目成果

OLUFUNMILAYO F. OLOPADE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT The overall goal of the dual-track University of Chicago Paul Calabresi Career Development Award for Clinical Oncology is to increase the number of highly skilled clinicians (M.D.s, D.O,s, Pharm.D., nurses with PhD or equivalent) and non-clinician postdoctoral researchers who are capable of designing and testing innovative hypothesis-driven clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II and Phase III trials). To do this, we have created a tightly structured and mentored education program within an academically rigorous training environment that prepares the most compelling senior fellows or junior faculty in clinical oncology for careers in patient oriented research. The program is anchored within our Comprehensive Cancer Center and led by Olufunmilayo Olopade, MD along with Walter Stadler, MD with strong support from an Executive Committee as well as Internal and External Advisory Committees. The 78 research training faculty preceptors have NIH or equivalent peer- reviewed funding, interact on a number of collaborative research and training efforts and are well qualified to serve as potential mentors for the five trainees per year participating in this K12 program. Each trainee is appointed for a minimum of two years. In this renewal application, we shall continue successful elements of the program in clinical pharmacology, genomics and immunotherapy while enhancing training opportunities in emerging fields of clinical informatics, data science and microbiome research. The Paul Calabresi K12 Scholars Program is our highly mentored, didactic coursework-intensive program, and “hands on” clinical research training which results in a Master of Science in Clinical Investigation. Leveraging clinical research infrastructure across University of Chicago Medicine, we have also created a flexible set of integrated interdisciplinary courses in translational science that blends entrepreneurships, cancer genomics, immunology, pharmacogenomics and community based clinical trials network. Of the 18 trainees who have completed the program since 2010, 13 (72%) are currently in academic careers, of whom 7 (54%) hold appointments at the Associate Professor level. Moreover, these 18 trainees have published a total of 176 oncology research papers, and are Principal Investigators or Co-Investigators on 56 oncology research grant awards. Of significance, 7 of 14 (50%) appointments to the program in the last funding cycle were women or members of underserved minority groups. An explicit goal of this Paul Calabresi Scholars program, as with all training programs in our institution, is that its training opportunities and benefits will extend far beyond the relatively few scholars whose stipends it will provide. The program has had a transformative and global impact and is reaching into the larger oncology trainee community in Chicago and to trainees in other countries who come to our Institution as Global Oncology Scholars. Thus, the benefit that accrues from the program's implementation and productivity is substantial and will increase the number of highly skilled clinicians and non-clinicians conducting cancer clinical trials.
期刊论文(53)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s11899-020-00597-y
发表时间: 2020-12
期刊: Current hematologic malignancy reports
影响因子: 2.9
作者: [Prescott K, Jacobs M, Stock W, Wynne J]
通讯作者: Wynne J
Bladder cancer pharmacogenomics: recent insights and future perspectives.
膀胱癌药物基因组学:最新见解和未来展望。
DOI: 10.2217/pgs.12.145
发表时间: 2012
期刊: Pharmacogenomics
影响因子: 2.1
作者: [O'Donnell,PeterH]
通讯作者: O'Donnell,PeterH
Radiation-Induced Differentiated Thyroid Cancer Is Associated with Improved Overall Survival but Not Thyroid Cancer-Specific Mortality or Disease-Free Survival.
放射诱导的分化型甲状腺癌与总体生存率改善相关,但与甲状腺癌特异性死亡率或无病生存率无关。
DOI: 10.1089/thy.2015.0634
发表时间: 2016
期刊: Thyroid : official journal of the American Thyroid Association
影响因子: --
作者: [White,MichaelG, Cipriani,NicoleA, Abdulrasool,Layth, Kaplan,Sharone, Aschebrook-Kilfoy,Briseis, Angelos,Peter, Kaplan,EdwinL, Grogan,RaymonH, Onel,Kenan]
通讯作者: Onel,Kenan
DOI: 10.1097/fpc.0000000000000413
发表时间: 2020-12
期刊: Pharmacogenetics and genomics
影响因子: 2.6
作者: [Truong TM, Lipschultz E, Schierer E, Danahey K, Ratain MJ, O'Donnell PH]
通讯作者: O'Donnell PH
34
    Scholars in Oncology Associated Research (SOAR)
    • 批准号:
      9793720
    • 项目类别:
    • 资助金额:
      $16.29万
    • 财政年份:
      2019
    • 负责人:
      OLUFUNMILAYO F. OLOPADE
    • 依托单位:
    Scholars in Oncology Associated Research (SOAR)
    • 批准号:
      10681395
    • 项目类别:
    • 资助金额:
      $14.15万
    • 财政年份:
      2019
    • 负责人:
      OLUFUNMILAYO F. OLOPADE
    • 依托单位:
    Scholars in Oncology Associated Research (SOAR)
    • 批准号:
      10219198
    • 项目类别:
    • 资助金额:
      $14.93万
    • 财政年份:
      2019
    • 负责人:
      OLUFUNMILAYO F. OLOPADE
    • 依托单位:
    Africa Cancer Leaders Institute
    • 批准号:
      9989080
    • 项目类别:
    • 资助金额:
      $3.0万
    • 财政年份:
      2017
    • 负责人:
      OLUFUNMILAYO F. OLOPADE
    • 依托单位:
    海外基金